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Abstract
Background/Aims: Combinations of treatments that have already received regulatory approval can offer additional
benefit over the treatments individually. However, trials of these combinations are lower priority than the development
of novel therapies, which can restrict funding, timelines and patient availability. Thus, this paper develops a novel
trial design to facilitate the evaluation of novel combination therapies. In general, this design combines elements of
phase II and phase III trials to reduce the administrative burden of undertaking these trials, whilst also maintaining
a feasible sample size.
Methods: This trial design uses response adaptive randomisation to increase the level of information collected about
successful novel drug combinations and Bayesian dose-response modelling to undertake a comparative-effectiveness
analysis for the most successful dose combination against a relevant comparator. We used simulation methods to
evaluate the probability of selecting the correct optimal dose combination and the frequentist and Bayesian operating
characteristics of this design for a trial in pain management and sedation in pediatric emergency departments. We
also compared the design to a standard frequentist trial with equal randomisation across the relevant comparator and
all considered dose combinations.
Results: With 410 participants and 5 interim updates of the randomisation ratio, we have an 83% chance of selecting
the correct optimal treatment. Based on this adaptive randomisation procedure, the comparative effectiveness analysis
has a the type I error of the trial of less than 5% and a power greater than 94%, for expected values of effectiveness
for the combination therapy. The trial offers an increase in power for all considered scenarios, compared to a trial
with equal randomisation and the predictive power of the trial is over 90%.
Conclusions: By simultaneously determining the optimal dose and collecting data on the relative effectiveness of an
intervention, we can minimise administrative burden and recruitment time for a trial. This will minimise the time
required to get effective, safe combination therapies to patients quickly. Furthermore, the proposed trial has high
potential to meet the dual study objectives within a feasible level of recruitment.
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Introduction
Investigator-initiated trials, where clinician investiga-
tors undertake their own trials,1 are key to expand-
ing the use of therapies that have already received
regulatory approval.2 One key expansion is the devel-
opment of therapies that combine two or more cur-
rently available interventions to improve outcomes
compared to either treatment alone.3–5 To develop
these novel combination therapies, we must determine
the optimal combination and evaluate the comparative
effectiveness of this optimal therapy against the current
standard of care.
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In the standard drug development process, these
two aims would require two trials; a phase II trial to
determine the optimal dose combination and a phase
III trial to evaluate the comparative effectiveness.6
However, initiating a trial is a time and resource
intensive process,7 especially when different funding
sources must be sought separately for each phase.
Thus, a trial design that incorporates both these
elements, whilst maintaining a reasonable level of
patient recruitment, would improve the efficiency of the
trial process, especially for investigator-initiated trials.
Seamless phase II/III trials that use a single study
protocol whilst moving between the investigative Phase
II and the confirmatory Phase III are the most common
type of adaptive trials.8 These trials typically combine
two distinct phases, where successful treatments are
‘taken forward‘ from Phase II to Phase III.9 In this
setting, Kimani et al. developed a seamless design
that incorporated dose selection based on safety and
efficacy.10 However, in this study we aim to identify
the optimal dose combination whilst also determining
its comparative effectiveness to a standard of care.
Thus, we develop a novel design to assess combination
therapies11 whilst also avoiding a formal delineation
of the two study phases. This maximises the time
available to assess the relative efficacy of the different
dose combinations.
To increase the expected allocation of patients to the
optimal dose combination, we use Bayesian response
adaptive randomisation to incrementally randomise
more patients to the dose combination with the
highest chance of being optimal.12,13 While adaptive
randomisation has typically been found to have limited
impact on the trial operating characteristics,14 we
found that adaptive randomisation has higher power
than an equal randomisation scheme. Typically, the
analysis of an adaptive trial requires adjustments to
ensure valid construction of confidence intervals and
p-values.15 However, we avoid this requirement by
proposing all analyses within a Bayesian framework.11
This paper presents our novel trial design that
simultaneously determines the optimal dose combina-
tion and its comparative effectiveness to a standard
comparator. We undertake simulations to determine
decision thresholds for the trial adaptions and compar-
ative Bayesian analyses.16 All thresholds are chosen
to ensure the trial has good frequentist operating
characteristics and a high chance of detecting the true
optimal treatment.17 We introduce a novel framework
that leads to an inconclusive trial outcome to suggest
additional data should be collected. We compare our
design to a standard frequentist design with equal
randomisation across the different dose combinations
and demonstrate superior operating characteristics for
our trial. Finally, we demonstrate that this design has
high Bayesian predictive power.
The development of this trial design was motivated
by an investigator-initiated trial looking at treatments
for procedural sedation within a paediatric emergency
department18 and is feasible conditional on the time
and resource constraints of the trial.
The Ketodex Trial
Procedural sedation and analgesia (PSA) is commonly
used to facilitate the realignment of a fractured or
dislocated limb without surgery in children (known
as a closed reduction).19,20 One drug often used
to provide PSA is Intravenous (IV) Ketamine.19
However, IV insertion is stressful and painful21 and,
thus, an alternative administration method would be
preferred, e.g. intranasal (IN) administration. There
is limited evidence that a combination of ketamine
and dexmedetomidine (ketodex) given intranasally
may offer adequate sedation.22,23 However, this
combination has not be trialled in patients undergoing
a closed reduction and so the Ketodex trial aims to:
(i) determine a suitable combination of IN ketodex
and
(ii) compare the efficacy of IN ketodex (novel
combination therapy) to IV ketamine (standard
of care).
As IN delivery of sedative agents is preferable to
inserting an IV, the Ketodex trial aims to determine
whether IN ketodex is non-inferior to IV ketamine.
The Ketodex trial has a binary primary outcome
where a ”success” is defined as a patient who is
adequately sedated for the duration of the closed
reduction procedure. As this outcome is available
within 24 hours of trial enrolment, it will be used
to assess both the efficacy of the different ketodex
combinations and the relative effectiveness of IN
ketodex to IV ketamine. Clinical expertise determined
that the ketodex trial will consider three dose
combinations for IN ketodex:
1. Ketamine dosed at 2 mg/kg in combination
with Dexmedetomidine dosed at 4 mcg/kg (2-4
ketodex)
2. Ketamine dosed at 3 mg/kg in combination
with Dexmedetomidine dosed at 3 mcg/kg (3-3
ketodex)
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3. Ketamine dosed at 4 mg/kg in combination
with Dexmedetomidine dosed at 2 mcg/kg (4-2
ketodex)
Methods
Figure 1 is a graphical representation of our novel trial
design, where the design and analysis consists of three
key phases, adaptive randomisation, dose response
modelling and a comparative effectiveness analysis.
Overall Sample Size
Before determining the full trial design, we selected
the overall sample size based on pragmatic concerns
and the Average Length Criterion (ALC) for Bayesian
sample size estimation.24,25 In general, ALC sets the
trial sample size by determining the smallest sample
size required to ensure that the posterior credible
interval has an average length below some fixed
constant ζ, to be specified. This design controls the
average length of the high-density posterior credible
interval of the difference in effectiveness between the
standard of care and the novel combination. In addition
to determining the overall sample size, we also use the
ALC to determine the randomisation ratio between
the novel combinations and the standard of care by
selecting the randomisation ratio that respects to
ALC. For the overall sample size calculation, we do
not consider any adaptive elements. However, our
simulations ensure that high power and well-controlled
type I error conditional on this sample size and the
proposed adaptive design.
Response-Adaptive Randomisation
Throughout the trial, we propose response-adaptive
randomisation to increase the number of participants
receiving effective dose combinations.12 To ensure
enough data for the comparative effectiveness analysis,
we fix the proportion of patients receiving the standard
of care and consider adaptive randomisation for dose
combinations. This requires a two-stage randomisation
procedure. Initially, R0 is the proportion of partic-
ipants randomised to receive the standard of care
and R1 = 1−R0 is the proportion of participants
randomised to receive the comparator. Following this,
participants are randomised to receive a specific dose
combination in a randomisation ratio that is updated
at each interim analysis (first panel in Figure 1). To
maintain blinding in the Ketodex trial, all participants
are randomised to a dose combination, even if they are
receiving the standard of care and the dose combina-
tion will be between two placebo agents.
Formally, the second randomisation step sets the
randomisation ratio ri,j across the different dose
combinations, i = 1, 2, 3, at each trial phase j =
1, . . . , J , where J is number trial phases (6 in Figure
1). In general, we set ri,j equal to the probability that
dose combination i is the optimal dose combination
based on the evidence gathered in all completed trial
periods;
ri,j = Prob
(
pi = max
i
{pi}
)
where pi is the probability of success for the dose
combination i, i = 1, 2, 3. The posterior distribution of
pi is obtained conditional on the data collected in trial
periods 1 to j.
Initially, we use the same prior distribution for
pi, i = 1, . . . , 3 so ri,1 =
1
3 , i.e., an equal number of
participants is randomised to each dose combination.
To avoid randomising a small number of participants
to a single arm, we use simulations to determine a
value γ such that we set ri,j = 0 when ri,j ≤ γ. In
these settings, we will adjust the values of ri,j so∑3
i ri,j = 1. Note that all trial data, irrespective of
whether ri ≤ γ, will be included in the final analysis
and a dose combination can be reinstated in the trial
randomisation scheme even if it was excluded in a
previous trial phase (see Figure 1, trial periods 4 and
5).
Finally, the practicalities of the Ketodex trial mean
that the second step randomisation is undertaken
without knowledge of the treatment group assignment
from the first randomisation. Thus, within each trial
period, the number of participants receiving each active
dose combination cannot be controlled and, assuming
that the number of participants to be enrolled in trial
period j is Nj , the number of participants randomised
to each active dose combination i will be a random
variable
Mi,j ∼ Binomial(Njri,j , R1).
Dose Response Modelling
To ensure maximal use of the collected data,
the primary effectiveness analysis will used a dose
response model to estimate the probability of success
pi for each dose combination i = 1, 2, 3.
11 Based
on expert opinion, the Ketodex trial uses a log-
logistic dose response model, with Xi the number
of successfully sedated participants among the Ni =∑J
1 Mi,j participants who receive dose i;
Xi ∼ Binomial(Ni, pi),
with
pi = β0 + β1 log(Ai) + β2 log(Bi),
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Figure 1. A graphical representation of the proposed trial design. The trial design and analysis consists of three key phases.
We use dose-response adaptive randomisation for patients receiving the novel combination (represented in the top half of the
Figure). Patients who receive the standard of care are also randomised to a dose combination of the placebo to maintain
blinding. In the second phase, we use Bayesian dose response modelling to determine the treatment with the maximum
expected probability of success, represented by the vertical lines in the top of the second panel. Finally, we compare the
effectiveness of the dose combination to the effectiveness of the standard of care by computing the probability that the
difference in effectiveness is below a given threshold. Conclusions following the trial are made based on thresholds λ1 and λ2,
chosen by simulation.
and Ai is dose for drug A (ketamine) and Bi is
the dose for drug B (dexamedetomidine). Alternative
dose response models may be more suitable in other
settings. However, in general, we do not consider
interaction terms as they cannot be reliably estimated
and models without interactions perform well in dose
finding studies.26
Using this dose response model, we can determine
the posterior for pi, i = 1, 2, 3. The optimal combina-
tion is then the dose combination with the maximum
expectation of pi. In Figure 1, the expected values
of pi are shown using vertical lines, with the highest
expected value associated with the first dose combina-
tion. Thus, we set p1 = pC , where pC is the probability
of a success for the optimal dose combination, used in
the comparative effectiveness analysis.
Comparative Effectiveness Analysis
The comparative effectiveness analysis compares pC
to pS , the probability of success for standard of care.
Specifically, we compute the posterior distribution of
d = pS − pC and then the probability that d is greater
than a pre-specified value η; y = P (d ≥ η). A standard
superiority trial would set η = 0 and conclude that the
novel combination is superior if y is small. However,
the Ketodex trial aims to determine that IN ketodex is
non-inferior to IV ketamine and, therefore, η is the non-
inferiority margin of 0.178. This non-inferiority margin
was estimated as the average non-inferiority margin
from two surveys of 204 clinicians, undertaken by the
Ketodex team. Again, evidence of non-inferiority is
shown by a small value for y.
As seen in Figure 1, the proposed trial has three
potential outcomes, that (i) the novel combination
comparator is superior (non-inferior for the Ketodex
trial), (ii) the trial is inconclusive or (iii) the standard
of care is superior. The trial conclusion is made using
two thresholds λ1 and λ2, chosen by simulation to
fix the type I and type II errors rates of the trial.
Specifically, if y ≤ λ1 then we conclude that the novel
combination is superior to the standard of care. If
y ≥ λ2, then we conclude that the standard of care
is superior to the novel combination. As λ1 + λ2 6= 1,
any values of y between λ1 and λ2 will be deemed
inconclusive, i.e., the currently available data are not
sufficient to determine whether the novel combination
or the standard of care is superior. This conclusion
would encourage the collection of more data that
could be added to this trial’s data to deliver definitive
conclusions.
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Simulation Scenarios
We use simulation methods to develop and evaluate
our trial design. To achieve this, we use five different
simulation scenarios to:
1. Evaluate the ALC to determine the overall
sample size and value for R0.
2. Determine the value of γ, the threshold under
which we drop a dose combination from the
randomisation procedure.
3. Determine the values of λ1 and λ2, the thresholds
for concluding superiority (non-inferiority) of the
novel combination or the standard of care.
4. Compare the Bayesian design with a frequentist
design with equal randomisation.
5. Compute the predictive power of the trial
These simulation scenarios are undertake sequentially,
i.e., the overall sample size is determined in the
first simulation and then used as the sample size
throughout the remaining simulation scenarios. The
following sections outlines the parameters of these five
simulations and the criteria used make conclusions
from the each simulation for the Ketodex trial.
Determining the Overall Sample Size For the Ketodex
trial, we set ζ = 0.07 and control the length of the 95%
highest density posterior credible interval. The value
for ζ represents a posterior credible interval that is
six times shorter than the credible interval from the
prior and was chosen considering the budget and time
constraints that limited our maximum recruitment.25
ALC determines the overall trial sample size and
R0, the proportion of participants randomised to the
standard of care. We consider four alternative values
for R0, 0.2, 0.3, 0.4 and 0.5, and compute the ALC for
each R0 for sample sizes increasing in increments of 10
from 350 to 500. Initially, we select the smallest sample
size that respects the ALC and then, for that sample
size, we select the value of R0 that leads to the most
balanced trial, provided the ALC is respected.
For each sample size and value of R0, we simulate
2000 datasets from the prior-predictive distribution
of the data, using the priors defined below. For each
dataset, we obtain 2000 simulations from the posterior
distribution of pS and pC and compute the highest
density posterior 95% credible interval.27 We then
estimate the average length for each sample size and
value of R0 across all 2000 prior-predictive datasets.
Determining γ for the adaptive randomisation Next,
we use simulations to determine the value of γ,
the threshold for dropping a given dose combination
from randomisation in a specific trial period. We
consider values of γ between 0.05 and 0.3, increasing
in increments of 0.05, with 0.3 chosen as the maximum
because an even randomisation ratio would have
0.33 randomised to each arm. For the simulations,
we fix, p1 = 0.93 with p2 = 0.88 and p3 = 0.83 and
determine the number of participants randomised
to each treatment option for each value of γ.
Across all simulations, we estimate the probability
of randomising the highest number of participants to
dose i = 1. We select the value of γ that maximises
this probability. If two values for γ give the same
probability, then we will chose the smallest threshold γ.
This allows us to maximise the amount of information
collected for the optimal treatment, if the incorrect
optimal treatment is selected.
We run 7000 simulations of the complete trial
recruitment for each value of γ. We use 7000
simulations as it gives a greater than 99% chance of
estimating the probability of 0.8 to 2 decimal places.
Thus, we base all conclusions on simulations results
rounded to 2 decimal places.
Thresholds for Comparative Effectiveness Analysis Based
on the adaptive randomisation scheme finalised in
the previous section, we then use simulation to
determine the decision thresholds for the comparative
effectiveness analysis, λ1 and λ2. As λ1 controls the
type I error of the trial, we set pS = 0.97 and pC =
0.97− η = 0.792 and select λ1 such that 5% of the
trials incorrectly conclude non-inferiority. For λ2, we
set pC = 0.78, undertake the same trial simulation
process and specify that 50% of the simulated trials
should declare superiority for the standard of care. In
both simulation settings, we set 3-3 ketodex as the
optimal treatment p1 = pC , based on expert guidance,
with 4-2 ketodex as the second best treatment p2 =
pC − 0.05 2-4 ketodex as the worst p3 = pC − 0.1.
We use 7000 simulated trials with the proposed
comparative effectiveness analysis based on 7000
posterior simulations from the dose response curve and
the posterior for pS .
Finally, to gain a fuller understanding of the
design, we then evaluate the probability of each
trial outcome, for 8 different values of pC ; pC =
0.93, 0.9, 0.87, 0.85, 0.83, 0.792, 0.78 and 0.75, using the
specified values of λ1 and λ2.
Frequentist Trial with Equal Randomisation We compare
our novel trial design with a trial that randomises
participants equally across all four treatments, i.e.,
the standard of care and the three dose combinations.
We use the same sample size for the our design and
this “equal randomisation” trial. We assume that the
final analysis for this equal randomisation trial will
compare each dose combination to the standard of care
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using an exact test for non-inferiority.28 We use an
exact test as pC = 0.97 making normal approximations
insufficiently accurate. We do not adjust for multiple
comparisons as we are expecting differences in the
treatment success. We estimate the size/power of
this trial for pC = 0.93, 0.9, 0.87, 0.85, 0.83, 0.792, 0.78
and 0.75, using the same assumptions about the
relative effectiveness of the dose combinations as
the simulations from the previous section and 7000
simulated trials for each value of pC .
Bayesian Predictive Power Finally, we calculate the
expected probability of a conclusive trial, i.e.,
conclusively concluding superiority of the novel
combination or the standard of care, using Bayesian
predictive power. We take 2000 simulations from the
prior predictive distributions of pC and pS , using the
priors outlined below. We consider three scenarios
where the relative effectiveness of the three dose
combinations to pC is varied. Scenario 1 sets the
relative effectiveness at 0.9, 0.95 and 1 for 4-2, 2-
4 and 3-3 ketodex, respectively. Similarly, Scenario 2
uses 0.95, 0.98 and 1 and Scenario 3 uses 0.95, 0.1
and 1.05. We undertake the comparative effectiveness
analysis using 2000 posterior simulations for each prior
predictive sample.
Prior Specification
To develop the design, we must specify priors for pS ,
the probability of success for the standard of care, β0,
β1 and β2, the parameters of the log-logistic model.
For the prior predictive analysis, we must also specify
a prior for pC . We use either previously published
evidence or minimally informative priors.
For IV ketamine, Kannikeswaran et al. had a 97%
success rate with ketamine dosed at 1.5 mg/kg, as
proposed in the Ketodex trial.29 To account for
differences between this trial and the Ketodex trial, we
down-weighted this information to an effective sample
size of 16;
pS ∼ Beta(15.6, 0.44).
For IN ketodex, Bhat et al. published a trial in which
2 out of 27 participants were inadequately sedated.23
To account for substantial differences between the two
trials, including in dosing and the setting, we discount
this information to an effective sample size of 6.5;
pC ∼ Beta(6.25, 0.25).
The effective sample size of the prior for pC was chosen
to give a 90% chance a priori that IV ketamine is
superior to IN ketodex, based on our non-inferiority
margin η = 0.178.
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Figure 2. The average length of the posterior highest density
credible interval for the four alternative values of R0, across
sample size. A black line represents the threshold of 0.07.
For the regression coefficients, we use non-central
Student t-distributions with precision 0.001 and
degrees of freedom 1, as suggested in Gelman et al..30
We set the mean for β1 and β2 to be 0, as we have
minimal information on the dose response. For β0, we
set the prior mean pi at 0.93, the success rate observed
in the literature.23
Results
Average Length Criterion
Figure 2 displays the results from the ALC analysis.
The average length of the posterior credible interval
falls below 0.07, represented by the black horizontal
line, with a sample size of 410 and R0 = 0.4. For all
sample sizes, R0 = 0.4 results in the shortest credible
intervals.
Based on this sample size, we specify the interim
analyses using pragmatic concerns. The first interim
analysis will take place after an expected enrolment
of 30 participants for each dose combination to
ensure sufficient data is collected before changing the
randomisation ratio. Thus, the first interim analysis
will take place once 150 participants have been
enrolled. Further updates of the randomisation ratio
will take place at intervals of 50 participants, i.e., at
150, 200, 250, 300, 350, before the final comparative
effectiveness analysis at 410.
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γ 0.05 0.1 0.15 0.2 0.25 0.3
Probability 0.83 0.82 0.82 0.83 0.83 0.83
Table 1. The probability of randomising the greatest number
of patients to the best dose combination, conditional on
different thresholds for dropping arms with limited evidence
of effectiveness.
Adaptive Randomisation: Choosing γ
Table 1 displays the probability of randomising the
highest number of people to the true optimal dose
combination. This probability is maximal when γ =
0.05, 0.2, 0.25, 0.3, with an 83% chance of randomising
the most people to the optimal treatment. Thus, we
chose the smallest value; γ = 0.05. In this setting, we
expect to enrol 137 patients to the optimal treatment
with an 95% interval between 56 and 190.
Comparative Effectiveness Analysis: Choosing
λ1 and λ2
Based on the overall sample size and the values for R0
and γ, we determine that λ1 = 0.0434 ensures a type
I error of 5% size. Following this, setting λ2 = 0.621
ensures that 50% of trials declare superiority for IV
ketamine when pC = 0.78. Based on these thresholds,
table 2 gives the probability of each trial outcome for
all the considered scenarios. The power of the Ketodex
trial is very high at the prior mean of 0.93 and remains
high provided the true probability of success for the
optimal dose combination is over 0.9. The probability
of an inconclusive trial is high for values of pC close
to the non-inferiority threshold. Finally, the trial is
more likely to be inconclusive above the non-inferiority
boundary, i.e., the probability of an inconclusive trial is
equal for pC = 0.85 and pC = 0.78, while 0.85 is 0.058
above the boundary and 0.78 is 0.012 below.
Frequentist Trial with Equal Randomisation
Table 2 displays the size or power for the equal
randomisation trial with frequentist analysis, enrolling
103 participants per arm. The equal randomisation
Ketodex trial has well-controlled size, despite not
correcting for multiple comparisons. Similar to the
Bayesian trial, the power of the equal randomisation
Ketodex trial is high at the prior mean for pC of
0.93. However, even for pC = 0.87, the power is low
at 0.57, decreasing still further as pC approaches
the non-inferiority boundary. Compared to our novel
design, the frequentist equal randomisation trial has
lower power at all considered value of pC . The
frequentist design has a smaller size at the non-
inferiority threshold, due to the use of exact tests as
the size of the test is less than 5%.
Predictive Power
The Bayesian predictive power of the Ketodex trial,
i.e., the prior probability that the Ketodex trial is
conclusive, is 0.92, 0.92 and 0.95 for scenarios 1, 2
and 3, respectively. The predictive power is higher for
scenario 3 as the optimal combination is assumed more
effective than the combination used in the literature.
In all considered settings, the predictive power is over
90%, which is higher than the prior probability that
IN ketodex is superior to IV ketamine. This is possible
as we allow conclusions that declare that IV ketamine
is superior to IN ketodex. The predictive power of
declaring non-inferiority is 0.83, 0.84 and 0.88 for
scenarios 1, 2 and 3, respectively.
Discussion
We have developed a novel Bayesian trial design that
simultaneously evaluates to comparative effectiveness
of a novel combination therapy and determines the
optimal dose combination. We use response adaptive
randomisation to maximise the number participants
who receive the higher performing dose combinations
and dose-response modelling to maximise the power of
the comparative effectiveness analysis. This trial design
minimises the administrative burden of evaluating
novel combination therapies and, although it has been
developed in a non-inferiority setting, can easily be
applied to trials to evaluate superiority of the novel
combination.
Our novel design has higher power than a trial
with equal randomisation and has high potential to
select the optimal dose combination. However, this
may be due to the fact that the Ketodex trial is a
non-inferiority trial with a rather large non-inferiority
margin, as estimated from a survery of clinicians. As
the non-inferiority margin gets smaller, the sample size
requirements for this novel design will increase and
other designs may be more suitable. Additionally, the
components of this novel design will need to be re-
estimated for alternative settings and this may change
the operating characteristics. To facilitate this re-
estimation, we the code to undertake the simulations
in the supplementary material. Furthermore, note that
there are other potential designs that could have been
considered alongside the proposed equal randomisation
trial such as separate phase II and phase III studies
or an alternative seamless design. However, as the
Ketodex trial included both dose combinations and
a non-inferiority analysis these designs would have
required adaptations to be relevant to our setting.
This novel design introduces the concept of an
inconclusive trial based on posterior probabilities. To
Prepared using sagej.cls
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Novel Bayesian Design Equal Randomised Frequentist Design
Probability of
Power Size
pC Non-inferiority Inconclusive Superiority
0.93 < 0.99 > 0.01 > 0.01 0.99 -
0.90 0.94 0.06 > 0.01 0.87 -
0.87 0.72 0.28 > 0.01 0.57 -
0.85 0.50 0.48 0.02 0.35 -
0.83 0.27 0.66 0.07 0.18 -
0.792 0.05 0.57 0.38 - 0.04
0.78 0.02 0.48 0.50 - 0.02
0.75 > 0.01 0.20 0.80 - > 0.01
Table 2. The operating characteristics of the novel Bayesian and equal randomisation frequentist trial designs. The Bayesian
design reports the probability of declaring non-inferiority, inconclusive trial result or superiority for different values of pC , the
probability of success for the optimal dose combination. The frequentist design reports size or power for different assumptions
about the probability of success under the optimal dose combination.
compute posterior probabilities, we must have a one-
sided test, i.e., we need to compute the probability that
novel combination is superior to standard of care. This
analysis would not be possible if we wanted to consider
a point hypothesis. Thus, an adaptation of this decision
rule would be required to be equivalent to a two-sided
test. Nonetheless, the advantage of this inconclusive
trial outcome and a Bayesian trial analysis is that
further information could be collected, past the initial
completion date of the trial, and incorporated with the
data from the currently proposed trial to assess the
comparative effectiveness going forward.
Finally, this novel design and decision making
framework could be extended to standard dose finding
settings to reduce the administrative burden of
undertaking phase II and phase III trials. However,
in this setting, the safety of the novel intervention
would also be needed an alternative potential designs
may be more suitable.10 The advantage of dose
combination studies is that the safety of the agents
is well understood so explicit safety monitoring and its
use in the response-adaptive randomisation may not be
required.
Conclusion
We have developed a novel trial design to undertake
dose finding and comparative effectiveness analysis
to subject to time and resource constraints of an
investigator initiated trial.
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